Colistin resistance in a clinical Acinetobacter baumannii strain appearing after colistin treatment: effect on virulence and bacterial fitness

Antimicrob Agents Chemother. 2013 Sep;57(9):4587-9. doi: 10.1128/AAC.00543-13. Epub 2013 Jul 8.

Abstract

The fitness and virulence costs associated with the clinical acquisition of colistin resistance by Acinetobacter baumannii were evaluated. The growth of strain CR17 (colistin resistant) was less than that of strain CS01 (colistin susceptible) when the strains were grown in competition (72-h competition index, 0.008). In a murine sepsis model, CS01 and CR17 reached spleen concentrations when coinfecting of 9.31 and 6.97 log10 CFU/g, respectively, with an in vivo competition index of 0.016. Moreover, CS01 was more virulent than CR17 with respect to mortality and time to death.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acinetobacter Infections / drug therapy
  • Acinetobacter Infections / microbiology
  • Acinetobacter Infections / mortality
  • Acinetobacter Infections / veterinary*
  • Acinetobacter baumannii / drug effects
  • Acinetobacter baumannii / genetics*
  • Acinetobacter baumannii / growth & development
  • Acinetobacter baumannii / pathogenicity
  • Animals
  • Anti-Bacterial Agents / pharmacology*
  • Colistin / pharmacology*
  • Colony Count, Microbial
  • Drug Resistance, Bacterial / drug effects
  • Drug Resistance, Bacterial / genetics
  • Female
  • Genetic Fitness / drug effects*
  • Mice
  • Mice, Inbred C57BL
  • Microbial Sensitivity Tests
  • Sepsis / drug therapy
  • Sepsis / microbiology
  • Sepsis / mortality
  • Sepsis / veterinary*
  • Survival Analysis
  • Virulence

Substances

  • Anti-Bacterial Agents
  • Colistin